» Articles » PMID: 25614179

Surgically Implanted and Non-invasive Vagus Nerve Stimulation: a Review of Efficacy, Safety and Tolerability

Overview
Journal Eur J Neurol
Publisher Wiley
Specialty Neurology
Date 2015 Jan 24
PMID 25614179
Citations 112
Authors
Affiliations
Soon will be listed here.
Abstract

Vagus nerve stimulation (VNS) is effective in refractory epilepsy and depression and is being investigated in heart failure, headache, gastric motility disorders and asthma. The first VNS device required surgical implantation of electrodes and a stimulator. Adverse events (AEs) are generally associated with implantation or continuous on-off stimulation. Infection is the most serious implantation-associated AE. Bradycardia and asystole have also been described during implantation, as has vocal cord paresis, which can last up to 6 months and depends on surgical skill and experience. The most frequent stimulation-associated AEs include voice alteration, paresthesia, cough, headache, dyspnea, pharyngitis and pain, which may require a decrease in stimulation strength or intermittent or permanent device deactivation. Newer non-invasive VNS delivery systems do not require surgery and permit patient-administered stimulation on demand. These non-invasive VNS systems improve the safety and tolerability of VNS, making it more accessible and facilitating further investigations across a wider range of uses.

Citing Articles

A pooled analysis of the side effects of non-invasive Transcutaneous Auricular Vagus Nerve Stimulation (taVNS).

Giraudier M, Ventura-Bort C, Szeska C, Weymar M Front Hum Neurosci. 2025; 19:1539416.

PMID: 39981126 PMC: 11841445. DOI: 10.3389/fnhum.2025.1539416.


Personalized auricular vagus nerve stimulation: beat-to-beat deceleration dominates in systole-gated stimulation during inspiration - a pilot study.

Tischer J, Szeles J, Kaniusas E Front Physiol. 2025; 15():1495868.

PMID: 39835202 PMC: 11743728. DOI: 10.3389/fphys.2024.1495868.


Next generation bioelectronic medicine: making the case for non-invasive closed-loop autonomic neuromodulation.

Lerman I, Bu Y, Singh R, Silverman H, Bhardwaj A, Mann A Bioelectron Med. 2025; 11(1):1.

PMID: 39833963 PMC: 11748337. DOI: 10.1186/s42234-024-00163-4.


Vagus nerve stimulation: a physical therapy with promising potential for central nervous system disorders.

Wang C, Wu B, Lin R, Cheng Y, Huang J, Chen Y Front Neurol. 2024; 15:1516242.

PMID: 39734634 PMC: 11671402. DOI: 10.3389/fneur.2024.1516242.


Hydrogels in wearable neural interfaces.

Yao M, Hsieh J, Tang K, Wang H Med X. 2024; 2(1):23.

PMID: 39659711 PMC: 11625692. DOI: 10.1007/s44258-024-00040-4.


References
1.
Stefan H, Kreiselmeyer G, Kerling F, Kurzbuch K, Rauch C, Heers M . Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: a proof of concept trial. Epilepsia. 2012; 53(7):e115-8. DOI: 10.1111/j.1528-1167.2012.03492.x. View

2.
Ben-Menachem E . Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol. 2003; 1(8):477-82. DOI: 10.1016/s1474-4422(02)00220-x. View

3.
Mauskop A . Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia. 2005; 25(2):82-6. DOI: 10.1111/j.1468-2982.2005.00611.x. View

4.
Sadler R, Purdy R, Rahey S . Vagal nerve stimulation aborts migraine in patient with intractable epilepsy. Cephalalgia. 2002; 22(6):482-4. DOI: 10.1046/j.1468-2982.2002.00387.x. View

5.
Amark P, Stodberg T, Wallstedt L . Late onset bradyarrhythmia during vagus nerve stimulation. Epilepsia. 2007; 48(5):1023-4. DOI: 10.1111/j.1528-1167.2007.01023.x. View